{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:24:43Z","timestamp":1771874683351,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK007356"],"award-info":[{"award-number":["DK007356"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Antiviral drugs are safe and effective in the third trimester to prevent intrauterine transmission of hepatitis B virus, and are recommended for hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) infected gravid mothers (between weeks 28 and 32) with high viral load, followed by postnatal hepatitis B immunization in the newborn. We estimated the comparative efficacy of antiviral drugs for prevention of vertical transmission of <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>, through a network meta\u2010analysis of clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive search of <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> EMBASE<\/jats:styled-content> and published proceedings from major liver meetings from January 1980 to November 2014. We conducted pair\u2010wise meta\u2010analyses and Bayesian framework using Markov chain Monte Carlo methods, combining direct and indirect evidence for any given pair of treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen clinical trials involving 2764 newborns of hepatitis B surface antigen seropositive mothers were eligible for analysis. There were no clinical trials involving tenofovir or entecavir. On pair\u2010wise meta\u2010analyses, telbivudine (hazard ratio, <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.12, 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0.04\u20130.37; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00%), and Lamivudine (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.40, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.24\u20130.65; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00%), were more effective than placebo in reducing vertical transmission of <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> in high viremic hepatitis B e antigen (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg)\u2010positive chronic Hepatitis B Chinese patients. Sensitivity analyses limited to studies with <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>eAg seropositive mothers revealed similar results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on a Bayesian network meta\u2010analysis of clinical trials, combining direct and indirect treatment comparisons, telbivudine appears to be more effective than Lamivudine for preventing vertical transmission of <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> infection. Trials assessing the efficacy of tenofovir or entecavir compared to placebo or other antiviral drugs are lacking.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.12959","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T15:50:14Z","timestamp":1441813814000},"page":"634-641","source":"Crossref","is-referenced-by-count":16,"title":["Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta\u2010analysis"],"prefix":"10.1111","volume":"36","author":[{"given":"Basile","family":"Njei","sequence":"first","affiliation":[{"name":"Section\u00a0of Digestive Diseases and Yale Liver Center Yale University School of Medicine New Haven CT USA"},{"name":"Investigative Medicine Program Yale Center of Clinical Investigation New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Gupta","sequence":"additional","affiliation":[{"name":"Section\u00a0of Digestive Diseases and Yale Liver Center Yale University School of Medicine New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oforbuike","family":"Ewelukwa","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology University of Florida Gainesville FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Ditah","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munoh","family":"Foma","sequence":"additional","affiliation":[{"name":"Division of Clinical Pathology University of Yaounde 1 Yaounde Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[{"name":"Section\u00a0of Digestive Diseases and Yale Liver Center Yale University School of Medicine New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.032"},{"key":"e_1_2_8_3_1","first-page":"531","article-title":"Asian\u2010Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw YF","year":"2012","journal-title":"Liver Int"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.083"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27034"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.043"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.06.005"},{"key":"e_1_2_8_9_1","first-page":"1019","article-title":"Effect on interruption of hepatitis B virus vertical transmission by lamivudine","volume":"22","author":"Feng HF","year":"2007","journal-title":"J Appl Clin Pediatr"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12379"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i7.1501"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.043"},{"key":"e_1_2_8_14_1","first-page":"77","article-title":"Study of Lamivudine in interruption of HBV intrauterine infection","volume":"21","author":"Shi MFLX","year":"2005","journal-title":"Clin Med Chin"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"e_1_2_8_16_1","first-page":"259","article-title":"The efficacy and safety of telbivudine in blocking intrauterine hepatitis B viral transmission","volume":"14","author":"Yao ZC","year":"2011","journal-title":"J Clin Hepatol"},{"key":"e_1_2_8_17_1","first-page":"443","article-title":"Clinical study of telbivudine to interrupt intrauterine transmission of hepatitis B virus","volume":"15","author":"Zeng YZS","year":"2010","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"e_1_2_8_18_1","first-page":"157","article-title":"Efficacy and safety of telbivudine in preventing mother\u2010to\u2010infant HBV transmission","volume":"12","author":"Zhang YF","year":"2010","journal-title":"Adverse Drug React J"},{"key":"e_1_2_8_19_1","first-page":"37","article-title":"Effects of Telbivudine joint hepatitis B vaccine and hepatitis B immunoglobulin to interrupt mother\u2010to\u2010child transmission:a randomized controlled trial of 60 cases","volume":"4","author":"Zhao DLX","year":"2010","journal-title":"Chin J Mod Drug Appl"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-86"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1761"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","unstructured":"ValkenhoefGTTZT BrockB.Hillege Haddis: a Support dssfe\u2010bmID.2013;55:459\u201375.","DOI":"10.1016\/j.dss.2012.10.005"},{"key":"e_1_2_8_25_1","first-page":"561","article-title":"Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients","volume":"17","author":"Zhang LJ","year":"2009","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1557-2"},{"key":"e_1_2_8_27_1","unstructured":"ShiZJ LX YangYB MaL.Clinical research on the interruption of mother to child transmission of HBV \u2013 a randomized double\u2010blind placebo\u2010control study. Unite for Site 6th Annual Global Health Conference New Haven (CT):Yale University 2009."},{"key":"e_1_2_8_28_1","first-page":"14","article-title":"Evaluation of therapeutic effect in HBV vertical transmission by lamivudine treatment combined with active\u2010passive immunization for pregnant women","volume":"2","author":"Xiang GJSJ","year":"2007","journal-title":"Chin Prac Med"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2270-0"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2187-3"},{"key":"e_1_2_8_31_1","unstructured":"Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus. Available athttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01488526. Accessed: 31 July 2015."}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12959","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:22:35Z","timestamp":1695547355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/liv.12959"],"URL":"https:\/\/doi.org\/10.1111\/liv.12959","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}